Pharmacovigilance and Drug Safety Software Market to Reach US$ 14.98 Billion by 2033 as AI-Driven Drug Monitoring Advances

According to DataM Intelligence, the global pharmacovigilance and drug safety software market was valued at US$ 7.56 billion in 2025 and is projected to reach US$ 14.98 billion by 2033, registering a CAGR of 10.8% during 2026-2033. Market expansion is supported by rising adverse drug reaction reporting, increasing clinical trial activity, and growing demand for regulatory-compliant drug safety management.

The industry is transitioning toward cloud-based platforms, artificial intelligence (AI), automated adverse event reporting, and advanced signal detection. Pharmaceutical companies and contract research organizations (CROs) are increasingly adopting digital solutions to improve case processing, strengthen safety surveillance, and manage complex regulatory requirements across global markets.

Download Free Sample Report: https://www.datamintelligence.com/download-sample/pharmacovigilance-and-drug-safety-software-market?indhu

Recent Developments in the Pharmacovigilance and Drug Safety Software Market

United States

✓ FDA AI Initiatives - 2026: The U.S. FDA continued advancing the use of artificial intelligence and digital tools in regulatory science, creating opportunities for automated safety-signal detection, adverse-event analysis and pharmacovigilance workflows.

✓ Real-World Data for Drug Safety - 2026: U.S. regulatory and healthcare organizations continued emphasizing real-world data and real-world evidence to monitor medicine safety after approval, strengthening demand for software that integrates clinical, claims and patient data.

✓ AI-Enabled Safety Monitoring - 2026: Pharmaceutical companies continued exploring AI-driven automation for adverse-event intake, case processing, medical coding and signal detection to reduce manual workloads and improve drug-safety oversight.

Japan

✓ PMDA Digital Safety Monitoring - 2026: Japan's Pharmaceuticals and Medical Devices Agency continued strengthening digital approaches to post-marketing safety surveillance, supporting more efficient adverse-event reporting and safety-risk evaluation.

✓ Electronic Adverse-Event Reporting - 2026: Japan continued using electronic reporting systems for adverse drug reactions, supporting more standardized safety-data collection and helping pharmaceutical companies meet regulatory reporting requirements.

✓ AI and Regulatory Science - 2026: Japanese regulatory and research organizations continued exploring data-driven approaches to medicine evaluation and safety monitoring, creating opportunities for advanced pharmacovigilance analytics and automated safety assessment.

Pharmacovigilance and Drug Safety Software Market Trends

AI-Powered Drug Safety Monitoring

AI and machine learning are creating opportunities to automate adverse event intake, extract relevant information from safety reports, identify potential safety signals, and prioritize cases for review. These capabilities can reduce manual workloads while supporting more consistent safety assessments.

Growing Adoption of Cloud-Based Platforms

Cloud-based deployment offers scalability, remote accessibility, and centralized safety data management. It is particularly relevant for organizations managing multinational clinical trials and pharmacovigilance operations, although data privacy, cybersecurity, and system validation remain important considerations.

Get 20% Complimentary Customization: https://www.datamintelligence.com/customize/pharmacovigilance-and-drug-safety-software-market?indhu

Market Segmentation

By Mode of Delivery

The market is segmented into on-premise, cloud-based, and other delivery models. Cloud-based solutions are gaining attention because they support scalability, centralized data access, and integration across distributed pharmaceutical operations. On-premise platforms remain relevant for organizations requiring greater control over internal infrastructure.

By Functionality

Key categories include issue tracking software, drug safety audit software, adverse event reporting software, and other functionalities. Adverse event reporting solutions support the collection, processing, and submission of safety information, while audit and issue-tracking tools help organizations maintain documentation and compliance workflows.

By End User

The market serves contract research organizations (CROs), biotechnology companies, healthcare providers, and other end users. CROs and biotechnology companies use these platforms to manage safety data across clinical development and post-market activities. Adoption is also supported by the need for standardized reporting and efficient safety oversight.

Key Players in the Pharmacovigilance and Drug Safety Software Market

Major companies operating in the market include Ennov Solutions Inc., Oracle Corporation, ArisGlobal LLC, EXTEDO, Clinevo Technologies, IQVIA, ICON plc, Parexel International Corporation, and AB Cube. These companies offer software platforms, clinical and regulatory technology, consulting, and related services supporting drug safety monitoring and pharmacovigilance operations.

Company Profiles

Oracle Corporation

Oracle provides enterprise software and cloud technologies used across pharmaceutical research and clinical development. Its healthcare and life sciences solutions support data management and digital workflows relevant to regulated environments.

ArisGlobal LLC

ArisGlobal develops life sciences software, including pharmacovigilance and regulatory solutions. Its LifeSphere platform supports drug safety processes, adverse event management, and regulatory operations.

IQVIA

IQVIA provides clinical research services, healthcare data analytics, and technology solutions. Its capabilities support pharmaceutical companies in clinical development, safety monitoring, and regulatory-related activities.

Purchase the Full Report: https://www.datamintelligence.com/buy-now-page?report=pharmacovigilance-and-drug-safety-software-market?indhu

Conclusion

The pharmacovigilance and drug safety software market is advancing as pharmaceutical companies face growing safety data volumes, complex regulatory obligations, and increasing expectations for patient protection. AI-enabled automation, integrated reporting, and cloud-based deployment are becoming important areas of technology development.

Through 2033, demand is expected to be influenced by clinical research expansion, digital transformation, and the need for efficient safety surveillance. Vendors that combine reliable compliance capabilities, scalable infrastructure, and advanced analytics will be well positioned to address evolving industry requirements.

FAQs

Q: What is the projected size of the pharmacovigilance and drug safety software market by 2033?

A: The market is projected to reach US$ 14.98 billion by 2033, growing at a CAGR of 10.8% during 2026-2033.

Q: What are the major applications of pharmacovigilance software?

A: Major applications include adverse event reporting, safety signal detection, drug safety audits, case processing, and post-market surveillance.

Q: Who are the key players in the market?

A: Major players include Oracle Corporation, ArisGlobal LLC, IQVIA, Ennov Solutions Inc., EXTEDO, Clinevo Technologies, and ICON plc.

Contact Us:
Sai Kiran
Business Development Manager
DataM Intelligence 4market Research LLP
6th Floor, M2 Tech Hub, Lalitha Nagar, Habsiguda,
Secunderabad, Hyderabad, Telangana 500039
USA: +1 877-441-4866
Email: Sai.k@datamintelligence.com

About Us :
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.